Parkinson disease IgG and C5a-induced synergistic dopaminergic neurotoxicity: Role of microglia

Neurochemistry International

Volumn 50, Issue 1, 2007, Pages 39-50

  Wang, Xi Jin ^a   Yan, Zhi Qiang ^b   Lu, Guo Qiang ^a   Stuart, Smith ^c   Chen, Sheng Di ^a,b  

^a SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

^b Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^c UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Complement; Dopaminergic neurotoxicity; Free radicals; Immunoglobulin; Microglia

Indexed keywords

COMPLEMENT COMPONENT C5A; FREE RADICAL; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G11; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G6; IMMUNOGLOBULIN G7; LEVODOPA; NITRIC OXIDE; SUPEROXIDE;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY COMBINING SITE; ARTICLE; ASTROCYTE; CELL ACTIVATION; CLINICAL ARTICLE; COCULTURE; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; EMBRYO; FEMALE; GLIA CELL; HUMAN; IMMUNOCYTOCHEMISTRY; MALE; MICROGLIA; NERVE DEGENERATION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; CELLS, CULTURED; COMPLEMENT C5A; DOPAMINE; IMMUNOGLOBULIN G; MICROGLIA; NEURONS; PARKINSON DISEASE; RATS;

EID: 33845434966     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2006.07.014     Document Type: Article

References (58)

1. Aloisi F. The role of microglia and astrocytes in CNS immune surveillance and immunopathology. Adv. Exp. Med. Biol. 468 (1999) 123-133
2. Aloisi F. Immune function of microglia. Glia 36 (2001) 165-179
3. Appel S.H., Le W.D., Tajti J., Haverkamp L.J., and Engelhardt J.I. Nigral damage and dopaminergic hypofunction in mesencephalon-immunized guinea pigs. Ann. Neurol. 32 (1992) 494-501
4. Barnum S.R. Complement biosynthesis in the central nervous system. Crit. Rev. Oral. Biol. Med. 6 (1995) 132-146
5. Beckman J.S., Carson M., Smith C.D., and Koppenol W.H. ALS, SOD and peroxynitrite. Nature 364 (1993) 584
6. Bradt B.M., Kolb W.P., and Cooper N.R. Complement-dependent proinflammatory properties of the Alzheimer's disease beta-peptide. J. Exp. Med. 188 (1998) 431-438
7. Chen S.D., Le W.D., Xie W.J., Alexianu M.E., Engelhardt J.I., Siklos L., and Appel S.H. Experimental destruction of substantia nigra initiated by Parkinson disease immunoglobulins. Arch. Neurol. 55 (1998) 1075-1080
8. Dahlstrom A., Wigander A., Lundmark K., Gottfries C.G., Carvey P.M., and McRae A. Investigations on auto-antibodies in Alzheimer's and Parkinson's diseases, using defined neuronal cultures. J. Neural. Transm. Suppl. 29 (1990) 195-206
9. Dawson T.M., Dawson V.L., and Snyder S.H. Molecular mechanisms of nitric oxide actions in the brain. Ann. N.Y. Acad. Sci. 738 (1994) 76-85
10. Defazio G., Dal Toso R., Benvegnu D., Minozzi M.C., Cananzi A.R., and Leon A. Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture. Brain Res. 633 (1994) 206-212
11. Emmerling M.R., Watson M.D., Raby C.A., and Spiegel K. The role of complement in Alzheimer's disease pathology. Biochim. Biophys. Acta 1502 (2000) 158-171
12. Facchinetti F., Dawson V.L., and Dawson T.M. Free radicals as mediators of neuronal injury. Cell. Mol. Neurobiol. 18 (1998) 667-682
13. Gao H.M., Hong J.S., Zhang W., and Liu B. Distinct role for microglia in rotenone-induced degeneration of dopaminergic neurons. J. Neurosci. 22 (2002) 782-790
14. Gao H.M., Jiang J., Wilson B., Zhang W., Hong J.S., and Liu B. Microglial activation- mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease. J. Neurochem. 81 (2002) 1285-1297
15. Gao H.M., Hong J.S., Zhang W., and Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J. Neurosci. 23 (2003) 1228-1236
16. Gao H.M., Liu B., Zhang W., and Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J. 17 (2003) 1954-1956
17. Gao H.M., Liu B., Zhang W., and Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J. 17 (2003) 1957-1959
18. Gayle D.A., Ling Z., Tong C., Landers T., Lipton J.W., and Carvey P.M. Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-alpha, interleukin-1beta, and nitric oxide. Brain Res. Dev. Brain Res. 133 (2002) 27-35
19. Greenamyre J.T., MacKenzie G., Peng T.I., and Stephans S.E. Mitochondrial dysfunction in Parkinson's disease. Biochem. Soc. Symp. 66 (1999) 85-97
20. Hasegawa E., Takeshige K., Oishi T., Murai Y., and Minakami S. 1-Methyl-4-phenylpyridinium (MPP+) induces NADH-dependent superoxide formation and enhances NADH-dependent lipid peroxidation in bovine heart submitochondrial particles. Biochem. Biophys. Res. Commun. 170 (1990) 1049-1055
21. He Y., Le W.D., and Appel S.H. Role of Fcgamma receptors in nigral cell injury induced by Parkinson disease immunoglobulin injection into mouse substantia nigra. Exp. Neurol. 176 (2002) 322-327
22. Hirsch E.C., Hunot S., Damier P., and Faucheux B. Glial cells and inflammation in Parkinson's disease: a role in neurodegeneration?. Ann. Neurol. 44 3 Suppl. 1 (1998) S115-S120
23. Jauneau A.C., Ischenko A., Chan P., and Fontaine M. Complement component anaphylatoxins upregulate chemokine expression by human astrocytes. FEBS Lett. 537 (2003) 17-22
24. Jenner P., and Olanow C.W. Understanding cell death in Parkinson's disease. Ann. Neurol. 44 Suppl. 1 (1998) S72-S84
25. Jeohn G.H., Kim W.G., and Hong J.S. Time dependency of the action of nitric oxide in lipopolysaccharide-interferon-gamma-induced neuronal cell death in murine primary neuron-glia co-cultures. Brain Res. 880 (2000) 173-177
26. Kidd P.M. Parkinson's disease as multifactorial oxidative neurodegeneration: implications for integrative management. Altern. Med. Rev. 5 (2000) 502-529
27. Kim W.G., Mohney R.P., Wilson B., Jeohn G.H., Liu B., and Hong J.S. Regional difference in susceptibility to lipopolysaccharide-induced neurotoxicity in the rat brain: role of microglia. J. Neurosci. 20 (2000) 6309-6316
28. Kinsner A., Pilotto V., Deininger S., Brown G.C., Coecke S., Hartung T., and Bal-Price A. Inflammatory neurodegeneration induced by lipoteichoic acid from Staphylococcus aureus is mediated by glia activation, nitrosative and oxidative stress, and caspase activation. J. Neurochem. 95 (2005) 1132-1143
29. Knott C., Stern G., and Wilkin G.P. Inflammatory regulators in Parkinson's disease: iNOS, lipocortin-1, and cyclooxygenases-1 and -2. Mol. Cell. Neurosci. 16 (2000) 724-739
30. Lacy M., Jones J., Whittemore S.R., Haviland D.L., Wetsel R.A., and Barnum S.R. Expression of the receptors for the C5a anaphylatoxin, interleukin-8 and FMLP by human astrocytes and microglia. J. Neuroimmunol. 61 (1995) 71-78
31. Lamoyi E. Preparation of F(ab′)2 fragments from mouse IgG of various subclasses. Meth. Enzymol. 121 (1986) 652-663
32. Lawson L.J., Perry V.H., Dri P., and Gordon S. Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 39 (1990) 151-170
33. Le W.D., Engelhardt J., Xie W.J., Schneider L., Smith R.G., and Appel S.H. Experimental autoimmune nigral damage in guinea pigs. J. Neuroimmunol. 57 (1995) 45-53
34. Le W.D., Rowe D.B., Jankovic J., Xie W., and Appel S.H. Effects of cerebrospinal fluid from patients with Parkinson disease on dopaminergic cells. Arch. Neurol. 56 (1999) 194-200
35. Le W.D., Rowe D., Xie W., Ortiz I., He Y., and Appel S.H. Microglial activation and dopaminergic cell injury: an in vitro model relevant to Parkinson's disease. J. Neurosci. 21 (2001) 8447-8455
36. Lee da Y., Oh Y.J., and Jin B.K. Thrombin-activated microglia contribute to death of dopaminergic neurons in rat mesencephalic cultures: dual roles of mitogen-activated protein kinase signaling pathways. Glia 51 (2005) 98-110
37. Liu B., Du L., and Hong J.S. Naloxone protects rat dopaminergic neurons against inflammatory damage through inhibition of microglia activation and superoxide generation. J. Pharmacol. Exp. Ther. 293 (2000) 607-617
38. Liu B., Wang K., Gao H.M., Mandavilli B., Wang J.Y., and Hong J.S. Molecular consequences of activated microglia in the brain: overactivation induces apoptosis. J. Neurochem. 77 (2001) 182-189
39. Liu B., and Hong J.S. Role of microglia in inflammation-mediated neurodegenerative diseases: mechanisms and strategies for therapeutic intervention. J. Pharmacol. Exp. Ther. 304 (2003) 1-7
40. Mabjeesh N.J., Frese M., Rauen T., Jeserich G., and Kanner B.I. Neuronal and glial γ-aminobutyric acid+ transporters are distinct proteins. FEBS Lett. 299 (1992) 99-102
41. McGeer P.L., Itagaki S., Akiyama H., and McGeer E.G. Rate of cell death in parkinsonism indicates active neuropathological process. Ann. Neurol. 24 (1988) 574-576
42. McRae-Degueurce A., Rosengren L., Haglid K., Booj S., Gottfries C.G., Granerus A.C., and Dahlstrom A. Immunocytochemical investigations on the presence of neuron-specific antibodies in the CSF of Parkinson's disease cases. Neurochem. Res. 13 (1988) 679-684
43. MÖller T., Nolte C., Burger R., Verkhratsky A., and Kettenmann H. Mechanisms of C5a and C3a complement fragment-induced (Ca2+)i signaling in mouse microglia. J. Neurosci. 17 (1997) 615-624
44. Morgan B.P., and Gasque P. Expression of complement in the brain: role in health and disease. Immunol. Today 17 (1996) 461-466
45. Morgan B.P., Gasque P., Singhrao S.K., and Piddlesden S.J. Role of complement in inflammation and injury in the nervous system. Exp. Clin. Immunogenet. 14 (1997) 19-23
46. O'Barr S., and Cooper N.R. The C5a complement activation peptide increases IL-1β and IL-6 release from amyloid-β primed human monocytes: implications for Alzheimer's disease. J. Neuroimmunol. 109 (2000) 87-94
47. Olanow C.W., and Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 22 (1999) 123-144
48. Qin L., Liu Y., Cooper C., Liu B., Wilson B., and Hong J.S. Microglia enhance β-amyloid peptide-induced toxicity in cortical and mesencephalic neurons by producing reactive oxygen species. J. Neurochem. 83 (2002) 973-983
49. Rowe D.B., Le W., Smith R.G., and Appel S.H. Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation. J. Neurosci. Res. 53 (1998) 551-558
50. Shen Y., Li R., McGeer E.G., and McGeer P.L. Neuronal expression of mRNAs for complement proteins of the classical pathway in Alzheimer brain. Brain Res. 769 (1997) 391-395
51. Shushakova N., Skokowa J., Schulman J., Baumann U., Zwirner J., Schmidt R.E., and Gessner J.E. C5a anaphylatoxin is a major regulator of activating versus inhibitory FcgammaRs in immune complex-induced lung disease. J. Clin. Invest. 110 (2002) 1823-1830
52. Smeyne M., Jiao Y., Shepherd K.R., and Smeyne R.J. Glia cell number modulates sensitivity to MPTP in mice. Glia 52 (2005) 144-152
53. Smith R.G., Hamilton S., Hofmann F., Schneider T., Nastainczyk W., Birnbaumer L., Stefani E., and Appel S.H. Serum antibodies to skeletal muscle-derived L-type calcium channels in patients with amyotrophic lateral sclerosis. N. Engl. J. Med. 327 (1992) 1721-1728
54. Suzdak P.D., Frederiksen K., Andersen K.E., Sorensen P.O., Knutsen L.J., and Nielsen E.B. NNC-711, a novel potent and selective γ-aminobutyric acid uptake inhibitor: pharmacological characterization. Eur. J. Pharmacol. 224 (1992) 189-198
55. Van Vugt M.J., Heijnen A.F., Capel P.J., Parki S.Y., Ra C., Saito T., Verbeek J.S., van de Winketl J.G., Smith L.C., Gotto Jr. A.M., and Dresel H.A. FcRγ-chain is essential for both surface expression and function of human FcγRI (CD64) in vivo. Blood 87 (1996) 3593-3599
56. Wang X., Chen S., Ma G., Ye M., and Lu G. Genistein protects dopaminergic neurons by inhibiting microglial activation. Neuroreport 16 (2005) 267-270
57. Wang X., Chen S., Ma G., Ye M., and Lu G. Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca(2+) disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech. Ageing Dev. 126 (2005) 1241-1254
58. Yamada T., McGeer P.L., and McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol. (Berl.) 84 (1992) 100-104